Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT07681596
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or stopped responding to prior treatments. The goal is to see if it is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD4045 (allogeneic CAR-T cells targeting BCMA), daratumumab, aldesleukin
- What this could lead to
- If successful, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial, so the treatment may not work or could cause serious side effects. The approach is complex and still experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Camperdown, 2050, Australia
-
Research Site
East Melbourne, 3002, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma